Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials
Conclusions.
The analyses demonstrated low to moderate individual-level surrogacy between PFS and OS. At the summary level, the surrogacy between PFS and OS varied significantly across different risk factors. With a short postprogression survival and a moderate correlation between PFS and OS, there is no evidence that PFS is a valid surrogate endpoint for OS in malignant mesothelioma. The Oncologist 2017;22:189–198
Implications for Practice: For better disease management and for more efficient clinical trial designs, it is important to know if progression-free survival (PFS) is a good surrogate endpoint for overall survival in malignant mesothelioma. With a relatively large database of 17 phase II trials and 716 patients from Cancer and Leukemia Group B and North Central Cancer Treatment Group, we conducted statistical analyses and found that there is no evidence to suggest that PFS is a valid surrogate endpoint for OS for malignant mesothelioma. Future research work is needed to find alternative surrogate endpoints for OS.
Source: The Oncologist - Category: Cancer & Oncology Authors: Wang, X., Wang, X., Hodgson, L., George, S. L., Sargent, D. J., Foster, N. R., Ganti, A. K., Stinchcombe, T. E., Crawford, J., Kratzke, R., Adjei, A. A., Kindler, H. L., Vokes, E. E., Pang, H. Tags: Lung Cancer Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Databases & Libraries | Leukemia | Lung Cancer | Mesothelioma | Statistics | Study